Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 5, 2024Open Access

Impact of minimal residual disease response and of status of disease on survival after Blinatumomab in B-Cell Acute Lymphoblastic Leukemia: results from a Real-Life Study. Running title: MRD-response and Disease Status correlate with survival after Blinatumomab in ALL-B patients

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSalvatore LeottaUniversity of CataniaUMUroš MarkovicAzienda Universitaria Ospedaliera Consorziale - Policlinico BariADAndrea DuminucoGuy's and St Thomas' NHS Foundation Trust

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Leotta et al. (2024) studied this question.

synapsesocial.com/papers/68e75a20b6db6435876d1cfbhttps://doi.org/10.21203/rs.3.rs-3988635/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia2017 · 602 citations
  2. 2Current concepts in the diagnosis and management of cytokine release syndrome2014 · 2,855 citations
  3. 3Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome2016 · 88 citations
  4. 4Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group2017 · 101 citations
  5. 5Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia2017 · 2,172 citations